David J. St. Jean

From Fragment Screening to In Vivo Efficacy: Optimization of a Series of 2-Aminoquinolines as Potent Inhibitors of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)

Yuan Cheng, Ted Judd, Michael D. Bartberger et al. · Journal of Medicinal Chemistry · 2011 · 141 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors

David J. Lloyd, David J. St. Jean, Robert J. Kurzeja et al. · Nature · 2013 · 98 citations

Life Sciences, Biochemistry, Pharmacology +14

Discovery of a Potent, Orally Active 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Clinical Study: Identification of (<i>S</i>)-2-((1<i>S</i>,2<i>S</i>,4<i>R</i>)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5<i>H</i>)-one (AMG 221)

Murielle M. Véniant, Clarence Hale, Randall W. Hungate et al. · Journal of Medicinal Chemistry · 2010 · 82 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Toward a General Route to the Eunicellin Diterpenes:  The Asymmetric Total Synthesis of Deacetoxyalcyonin Acetate

Gary A. Molander, David J. St. Jean, Julia Haas · Journal of the American Chemical Society · 2004 · 70 citations

Natural Sciences, Chemistry, Drug Discovery +9

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

Leonard Buckbinder, David J. St. Jean, Trang Tieu et al. · Cancer Discovery · 2023 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16